Abstract
With the advent of new, particularly mixed-oil lipid emulsions approved by the United States Food & Drug Administration (FDA), clinicians have more options when choosing one as part of the parenteral nutrition support of patients. Lipid products long-standing availability in Europe and other parts of the world has certainly facilitated the process in the United States, where there was little evolution before 2014. These newer oil-based emulsions are finding their way to be used in pediatrics, as studies are being carried out that will result in pediatric labeling. Pediatric clinicians may find themselves wondering how these lipid emulsions are different from those that have come before; whether the same dosing or administration practices apply as with the traditional soybean-oil lipid emulsion, and if they can be used for other more emergent interventions. We present this review of the current lipid emulsions available in the U.S. market, highlighting the differences among them, as well as, providing some practical information for clinicians that can assist them in their day-to-day duties.
Highlights
Parenteral nutrition (PN) as a medical intervention has been a part of clinical practice since the 1970s
With the advent of new, mixed-oil lipid emulsions approved by the United States Food & Drug Administration (FDA), clinicians have more options when choosing one as part of the parenteral nutrition support of patients
Reduction in triglyceride levels of approximately 70 mg/dL has been observed when patients are switched from olive oil based emulsions to those with multiple sources, suggesting that more complex emulsions may be beneficial in avoiding hypertriglyceridemia [25]
Summary
Parenteral nutrition (PN) as a medical intervention has been a part of clinical practice since the 1970s. Injectable lipid emulsions (ILEs) are advantageous to clinicians, providing caloric density, and essential fatty acids in an iso-osmolar dosage form. More recent studies have indicated that emulsions with a combination of soy, olive, and fish oils in addition to medium-chain triglycerides (MCTs) may be more beneficial through down-regulation of inflammation, immunomodulation, and potentially improving clinical outcomes [3]. Notable studies indicating harm or benefit shall be included in the analyses of these ILEs. For general information related to the administration, dosing, storage, preparation, and general risks, such as infection associated with the administration of IV preparations, package inserts and clinical practice guidelines should be referenced.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
